Top 10 Companies in the (R)-(-)-2-Butanol (CAS 14898-79-4) Market (2026): Market Leaders Powering Global Chemistry

MARKET INSIGHTS

Global (R)-(-)-2-Butanol (CAS 14898-79-4) market size was valued at USD 28.4 million in 2025 and is projected to rise to USD 46.2 million by 2034, reflecting a CAGR of 5.1 % over the forecast period.

(R)-(-)-2-Butanol is a chiral secondary alcohol (C₄H₁₀O) that delivers high optical purity and a specific levorotatory configuration. It functions as a pivotal chiral building block and resolving agent across asymmetric synthesis, pharmaceutical intermediates, and fine chemical production. Its role extends to flavor, fragrance, solvent, and specialty chemical manufacturing where stereochemical precision is mandatory.

Demand growth is anchored in the pharmaceutical sector, where enantiopure APIs are increasingly critical for therapeutic efficacy and safety. Expansion in asymmetric catalysis research and the adoption of green chemistry practices further reinforce market momentum. Leading producers such as TCI Chemicals, Sigma‑Aldrich (Merck KGaA), and Alfa Aesar maintain robust chiral chemical portfolios.

(R)-(-)-2-Butanol (CAS 14898-79-4) Market – View in Detailed Research Report

Top 10 Companies in the (R)-(-)-2-Butanol (CAS 14898-79-4) Market

1️⃣ BASF SE

Headquarters: Ludwigshafen, Germany
Key Offering: Pharmaceutical‑grade (R)-(-)-2-Butanol, advanced asymmetric catalysts, and specialty solvents

BASF’s integrated production network delivers high‑purity enantiomers to pharma, fine chemicals, and flavor & fragrance clients. The company’s investment in process intensification and enzyme‑based resolution has cut production costs while maintaining superior optical purity.

Sustainability/Growth Initiatives:

• Biocatalytic resolution processes that lower energy use by 35 %
• Carbon‑neutral manufacturing targets for 2035
• Strategic partnerships with contract manufacturers in Asia-Pacific to expand regional supply

2️⃣ Tokyo Chemical Industry (TCI)

Headquarters: Tokyo, Japan
Key Offering: High‑purity chiral alcohols, specialty solvents, and resolution catalysts

TCI’s focus on scalable enzymatic resolution and cost‑effective kinetic processes positions it as a preferred supplier for pharma outsourcing and fine chemical R&D. Its R&D pipeline includes engineered enzymes for higher enantiomeric excess.

Sustainability/Growth Initiatives:

• Implementation of continuous flow reactors to boost throughput
• Investment in renewable feedstocks for chiral synthesis
• Collaboration with universities to accelerate biocatalysis innovation

3️⃣ Merck KGaA

Headquarters: Darmstadt, Germany
Key Offering: Pharmaceutical intermediates, chiral auxiliaries, and specialty solvents

Merck’s vertically integrated manufacturing and proprietary asymmetric catalysts ensure consistent supply of high‑purity (R)-(-)-2-Butanol to global pharma clients. The company’s focus on precision chemistry aligns with emerging precision‑medicine pipelines.

Sustainability/Growth Initiatives:

• Green chemistry roadmap targeting 25 % reduction in solvent use by 2030
• Investment in enzyme engineering for cost‑effective resolution
• Strategic acquisitions of niche chiral suppliers to broaden portfolio

4️⃣ DSM‑Firmenich AG

Headquarters: Heerlen, Netherlands / Basel, Switzerland
Key Offering: High‑purity chiral intermediates, flavor & fragrance compounds, and specialty solvents

DSM‑Firmenich leverages its dual expertise in chemistry and fragrance to supply chiral alcohols with exceptional purity for both pharma and flavor markets. The merger has expanded its chiral fine‑chemical capabilities and market reach.

Sustainability/Growth Initiatives:

• Adoption of biobased feedstocks for chiral synthesis
• Implementation of circular economy practices in solvent recovery
• Partnerships with pharma giants for joint R&D on green processes

5️⃣ Evonik Industries AG

Headquarters: Essen, Germany
Key Offering: Specialty chemicals, chiral auxiliaries, and high‑purity solvents

Evonik’s focus on high‑performance materials and specialty chemicals extends to chiral intermediates. Its global network supports rapid delivery to pharma and fine‑chemical clients.

Sustainability/Growth Initiatives:

• Targeted reduction of CO₂ emissions across production facilities
• Investment in scalable asymmetric synthesis technologies
• Collaboration with academic institutions on green chemistry projects

6️⃣ Lonza Group AG

Headquarters: Basel, Switzerland
Key Offering: Custom chiral synthesis, enzyme‑based resolution, and specialty solvents

Lonza’s contract‑manufacturing model enables tailored chiral solutions for pharma and biotech clients. Its expertise in biocatalysis and process scale‑up supports high‑volume production.

Sustainability/Growth Initiatives:

• Implementation of renewable energy across manufacturing sites
• Development of low‑toxicity solvents for green processes
• Strategic alliances with biotech firms to expand chiral portfolios

7️⃣ Codexis, Inc.

Headquarters: Emeryville, California, USA
Key Offering: Enzyme engineering, biocatalytic resolution, and custom chiral synthesis

Codexis pioneers engineered enzymes that deliver high‑selectivity resolution of racemic mixtures, reducing cost and improving scalability for chiral alcohols. The company’s technology platform is increasingly adopted by pharma and fine‑chemical manufacturers.

Sustainability/Growth Initiatives:

• Reduction of solvent usage through enzyme‑driven processes
• Investment in digital process optimization for real‑time quality control
• Partnerships with pharma leaders to co‑develop green synthesis routes

8️⃣ Capot Chemical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Cost‑effective chiral alcohols, resolution catalysts, and specialty solvents

Capot Chemical’s focus on scalable enzymatic resolution and cost‑efficient production makes it a key supplier for emerging pharma markets in China and India.

Sustainability/Growth Initiatives:

• Adoption of renewable feedstocks for chiral synthesis
• Implementation of closed‑loop solvent recovery systems
• Expansion of R&D capabilities in enzyme technology

9️⃣ Biosynth

Headquarters: Basel, Switzerland
Key Offering: High‑purity chiral intermediates, specialty solvents, and enzyme‑based resolution

Biosynth’s niche focus on high‑purity chiral intermediates supports specialty chemical and pharma applications, especially where regulatory compliance demands stringent purity.

Sustainability/Growth Initiatives:

• Investment in green chemistry R&D for solvent alternatives
• Use of renewable energy sources in production
• Collaboration with contract manufacturers to broaden market reach

🔟 Shanghai Trustin Chemical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Chiral alcohols, resolution catalysts, and specialty solvents

Shanghai Trustin’s focus on high‑quality chiral intermediates and efficient resolution processes supports both domestic and international clients in pharma and fine‑chemical sectors.

Sustainability/Growth Initiatives:

• Implementation of energy‑efficient production lines
• Development of low‑toxicity solvents for green processes
• Strategic partnerships with global pharma companies for joint R&D

Download FREE Sample Report

Get Full Report Here

Outlook

Over the next decade, the (R)-(-)-2-Butanol market is expected to grow from USD 29.7 million in 2026 to USD 46.2 million by 2034, driven by the convergence of pharmaceutical demand for enantiopure APIs, expanding flavor and fragrance applications, and a global push for greener synthesis routes. The Asia‑Pacific region, which currently accounts for 45 % of market share, is projected to expand at a 7 % CAGR, supported by cost‑efficient manufacturing and robust R&D ecosystems.

Future Trends

Key emerging trends include the broader adoption of engineered enzymes that cut production costs by up to 30 % and the integration of biocatalytic processes into oligonucleotide synthesis and peptide manufacturing. The rising interest in chiral polymers and advanced materials is creating new revenue streams for suppliers that can deliver high‑purity intermediates at scale. Precision medicine initiatives and stricter regulatory requirements for stereochemistry are also amplifying demand for (R)-(-)-2-Butanol as a chiral building block.